80 healthy participants and 80 Early Stage Alzheimer Disease (AD) patients.
Conditions
Interventions
The digitized tests will be administered to 80 Early Stage Alzheimer Disease (AD) patients and 80 healthy participants (their partner or relative) and. The study requires a single visit to the patient
Sponsors
Philips Research Eindhoven
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, an AD patient must meet all of the following criteria: 1. Aged 60 and older 2. Fluent/correct speaker in Dutch 3. AD patient is able to give consent 4. AD diagnosis by a clinical specialist, such as a geriatrician or neurologist 5. Being able to perform the neuropsychological tests with an Ipad 6. AD patient living at home (not at a nursing home) 7. Date of AD diagnosis < 2yr In order to be eligible for participation in this study, a healthy participant must meet the following criteria: 1. Partner of relative of a patient with AD 2. Fluent/correct speaker in Dutch 3. Able to provide informed consent 4. Aged 60 and older
Exclusion criteria
Exclusion criteria: A potential AD patient who meets any of the following criteria will be excluded from participation in this study: 1. Unable or incompetent to give written informed consent 2. Severe communication deficits 3. Unable and/or unwilling to use a tablet to perform the tests 4. Medical history of neurological and/or psychiatric disorders (except for AD) 5. Mild Cognitive Impairment (MCI), vascular dementia, frontotemporal or mixed dementia diagnosis 6. Traditional neuropsychological assessment in the last 6 months 7. Bad eyesight or hearing, even with correction 8. Unable to properly use hands 9. An average alcohol consumption of 4 or more units per day 10. Use of one or more of the following types of medicine: antipsychotics, benzodiazepines, antidepressants, opioids, lithium, anti-epileptics, anti- Parkinson medication 11. Use of drugs A potential healthy participant who meets any of the following criteria will be excluded from participation in this study: 1. Unable or incompetent to give written informed consent 2. Medical history of neurological and/or psychiatric disorders 3. Traditional neuropsychological assessment in the last 6 months 4. Bad eyesight or hearing, even with correction 5. Unable to properly use hands 6. An average alcohol consumption of 4 or more units per day 7. Use of one or more of the following types of medicine: antipsychotics, benzodiazepines, antidepressants, opioids, lithium, anti-epileptics, anti- Parkinson medication 8. Use of drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of the study is to collect digital data for the (digital) tests that are currently hosted on the Cognitive Dx platform and to use this data to develop and refine the existing algo-rithms that automatically score the test. The algorithms will be developed and refined based on the manual scores from the neuropsychologist. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To compare specific digital measures, or combination of digital measures, that are gen-erated by the algorithms and to discover if these are different for Alzheimer patients as compared to healthy individuals. 2.Evaluate the usability of the digitized test platform in the healthy and AD population | — |
Contacts
Public ContactCeline Reverseau
Philips Research Eindhoven
Outcome results
None listed